There are currently 129 active clinical trials seeking participants for Multiple Sclerosis research studies. The states with the highest number of trials for Multiple Sclerosis participants are Florida, New York, California and Texas.
Blood Flow Restriction And Veterans With MS
NCT05433103
Recruiting
There currently is a lack of evidence to support exercise interventions in people with advanced disability due to MS (i.e., need assistance to walk or use a wheelchair). This project proposes to study a strength training program using blood flow restriction (BFR) in people with advanced disability due to MS. BFR uses a device that partially blocks blood flow to the exercising limb and causes a response in the muscle which can replicate the effects of high-intensity training using much lower inte... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/13/2025
Locations: Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado
Conditions: Multiple Sclerosis
Register for Updates
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201
Recruiting
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/13/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +37 locations
Conditions: Multiple Sclerosis, Myasthenia Gravis
Register for Updates
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
NCT05269628
Recruiting
The purpose of this research study is to compare the effects of cannabidiol (CBD), tetrahydrocannabinol (THC), or both, on sleep and pain in persons with multiple sclerosis (MS). Little is known about how CBD and/or THC may help sleep, reduce pain, or perhaps even treat pain through better sleep.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/11/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Multiple Sclerosis, Sleep, Pain
Register for Updates
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criter... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/10/2025
Locations: Alabama Neurology Associates- Site Number : 8400115, Birmingham, Alabama +275 locations
Conditions: Multiple Sclerosis
Register for Updates
Functional Balance Intervention in Multiple Sclerosis
NCT06341023
Recruiting
This project involves two sub-parts: Study 1: Effect of lab-based Functional Balance Intervention (FBI) for physical and cognitive symptoms of Multiple Sclerosis. Study 2: Feasibility of home-based FBI for physical and cognitive symptoms of Multiple Sclerosis. Each study involves a 2-arm, Phase-1, randomized controlled clinical trial to evaluate the effect of FBI on physical, cognitive function, and daily living among people with MS (PwMS). Study 1 is conducted in a lab setting, while Study 2... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/10/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Multiple Sclerosis
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/05/2025
Locations: Alabama Neurology Associates- Site Number : 8400115, Birmingham, Alabama +313 locations
Conditions: Multiple Sclerosis
Register for Updates
A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis
NCT06197685
Recruiting
The goal of this novel study is to compare the effect of a combined cognitive rehabilitation and exercise approach on new learning and memory (NLM) in persons with multiple sclerosis (pwMS) and mobility disability.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/03/2025
Locations: Kessler Foundation, East Hanover, New Jersey
Conditions: Multiple Sclerosis
Register for Updates
NYSCF Scientific Discovery Biobank
NCT06203106
Recruiting
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.
Gender:
ALL
Ages:
30 days and above
Trial Updated:
02/27/2025
Locations: New York Stem Cell Foundation Research Institute, New York, New York
Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Register for Updates
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
NCT06433765
Recruiting
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
Gender:
FEMALE
Ages:
Between 15 years and 50 years
Trial Updated:
02/27/2025
Locations: BRIUMVI® Pregnancy Registry Virtual Research Coordination Center, Wilmington, North Carolina
Conditions: Multiple Sclerosis
Register for Updates
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113
Recruiting
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS). The study will include lactating mothers who plan to breastfeed and initiate/re-initiate ofatumumab 2-24 weeks post-partum.
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
02/27/2025
Locations: UCSF, San Francisco, California +8 locations
Conditions: Multiple Sclerosis
Register for Updates
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
NCT05849467
Recruiting
Background: Multiple sclerosis (MS) and progressive multifocal leukoencephalopathy (PML) are disorders that affect the central nervous system (CNS). The CNS includes the brain, spinal cord, and optic nerves. Both diseases can cause muscle weakness and impair vision, speech, and coordination. Researchers are working to better understand how MS and PML affect the CNS. Objective: To test whether an experimental radioactive tracer (minibody) can help positron emission tomography (PET) scans detect... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/26/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Register for Updates
Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects
NCT04699747
Recruiting
Our overall objective is to obtain an initial assessment of the potential value of using \[18F\]3F4AP for imaging demyelinating diseases such as multiple sclerosis: * Aim 1) Assess the safety of \[18F\]3F4AP in healthy volunteers and subjects with multiple sclerosis (MS). Hypothesis 1: Administration of \[18F\]3F4AP will result in no changes in vitals or other adverse events. * Aim 2) Assess the pharmacokinetics of a bolus infusion of \[18F\]3F4AP in humans including healthy volunteers and MS p... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/25/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Multiple Sclerosis
Register for Updates